BD Veritor System Bedienungsanleitung Seite 126

Technical Support
For questions, or to report a problem, please call Technical Support at 1.800.638.8663. Test system problems may
also be reported to the FDA using the MedWatch reporting system (phone: 1.800.FDA.1088; fax: 1.800.FDA.1078; or
http://www.fda.gov/medwatch).
AVAILABILITY
Cat. No. Description
256045 BD Veritor™ System for Rapid Detection of Flu A+B, 30 tests
256051 BD Veritor™ System Flu A+B Control Swab Set, 10 pairs of swabs
220252 COPAN Flexible Minitip Flocked Swab, 100 swabs
256066 BD Veritor™ Plus Analyzer
256068 BD Veritor™ InfoScan Module
443907 USB Printer Cable for BD Veritor™ Analyzer
256038 BD Veritor™ System for Rapid Detection of Respiratory Syncytial Virus (RSV)
To network a BD Veritor Plus Analyzer to an LIS, contact BD Technical Services for details.
REFERENCES
1. Simonsen L., Fukuda K, Schonberger LB, Cox NJ. Impact of influenza epidemics on hospitalizations. J. Infect. Dis. 2000;
181:831–7
2. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the
United States. JAMA 2003: 289:179–86
3. Treanor, J.J., Hayden, F.G., Vrooman, P.S., et al. 2000. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir
in treating acute influenza: a randomized controlled trial. JAMA. 283:1016–1024.
4. Kaiser, L., Couch, R.B., Galasso, G.J., Glezen, W.P., Webster, R.G., Wright, P.F., and Hayden, F.G. 1999. First
international symposium on influenza and other respiratory viruses: summary and overview Kapalua, Maui, Hawaii,
December 4–6, 1998. Antiviral Res., 42:149–176
5. Cox, N.J., and Bender, C.A. 1995. The molecular epidemiology of influenza viruses. Virology, 6:359–370.
6. Todd, S.J., Minnich, L., and Waner, J.L. 1995. Comparison of rapid immunofluorescence procedure with TestPack RSV
and Directigen Flu A for diagnosis of respiratory syncytial virus and influenza A virus. J. Clin. Microbiol.33:1650–1651.
7. Harris, P.O. 1989. Clinical relevance and efficient detection of seven major respiratory viruses. ACL. p. 15–19.
8. McElhaney, J.E., Gravenstein, S., Krause, P., Hooton, J.W., Upshaw, C.M., and Drinka, P. 1998. Assessment of markers of
the cell-mediated immune response after influenza virus infection in frail older adults. Clin. Diag. Lab. Immunol. 5:840–844.
9. Fan, J., Henrickson, K.J., and Savatski, L.L. 1998. Rapid simultaneous diagnosis of infections with respiratory syncytial
viruses A and B, influenza viruses A and B, and human parainfluenza virus types 1, 2, and 3 by multiplex quantitative
reverse transcription-polymerase chain reaction-hybridization assay (hexaplex). Clin. Infect. Disease 26:1397–1402.
10. Wright, K.E., Wilson, G.A.R., Novosad, D., Dimock, C., Tan, D., and Weber, J.M. 1995. Typing and subtyping of influenza
viruses in clinical samples by PCR. J. Clin. Microbiol.33:1180–1184.
11. Kendal, A.P. 1985. Influenza Viruses. p. 341–357. Laboratory Diagnosis of Viral Infections, In H. Lennette, (ed.) Marcel
Dekker, Inc., New York.
12. McQuillen, J., Madeley, C.R., and Kendal, A.P. 1985. Monoclonal antibodies for the rapid diagnosis of influenza A and B
virus infections by immunofluorescence. Lancet.ii: 911–914.
13. Guenthner, S.H., and Linnemann, C.C., Jr. 1988. Indirect immunofluorescence assay for rapid diagnosis of influenza
virus. Laboratory Medicine.19:581–583
14. Minnick, L.L., and Ray, C.G. 1986. Early testing of cell cultures for detection of hemadsorbing viruses. J. Clin. Microbiol.
25:421–422.
15. Schmidt, N.J., Ota, M., Gallo, D., and Fox, V.L. 1982. Monoclonal antibodies for rapid, strain specific identification of
influenza virus isolates. J. Clin. Microbiol.16:763–765.
16. Clinical and Laboratory Standards Institute. 2005. Approved Guideline M29-A3. Protection of laboratory workers from
occupationally acquired infections, 3rd ed. CLSI, Wayne, Pa.
17. Garner, J.S. 1996. Hospital Infection Control Practices Advisory Committee, U.S. Department of Health and Human
Services, Centers for Disease Control and Prevention. Guideline for isolation precautions in hospitals. Infect. Control
Hospital Epidemiol.17:53–80.
18. U.S. Department of Health and Human Services. 2007. Biosafety in microbiological and biomedical laboratories, HHS
Publication (CDC), 5th ed. U.S Government Printing Office, Washington, D.C.
19. Directive 2000/54/EC of the European Parliament and of the Council of 18 September 2000 on the protection of workers
from risks related to exposure to biological agents at work (seventh individual directive within the meaning of Article 16(1)
of Directive 89/391/EECP). Office Journal L262, 17/10/2000, p.021–0045.
Technical Information: In the United States contact BD Technical Service and Support at 1.800.638.8663 or bd.com.
16